Oxford Cancer Biomarkers partners with Mira Precision Health to advance its ToxNav® test for predicting patient toxicity to 5FU/capecitabine treatment in the USA
OXFORD, England and MASON, Ohio, June 2, 2025 /PRNewswire/ -- Following the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, Oxford Cancer Biomarkers Ltd (OCB), a leader in molecular precision cancer diagnostic tests, has today announced a new partnership with Mira Precision Health Inc to advance OCB's proprietary ToxNav® test in the USA. ToxNav® is a revolutionary precision oncology test that identifies patients most at risk of undergoing severe toxicity upon treatment with 5FU/capecitabine, which, in extreme cases, can lead to the patient's death. Mira Precision Health, headquartered at the Mason 5155 BioHub—a dynamic biology and technology center in Mason, Ohio, USA—is dedicated to advancing precision medicine by delivering innovative solutions that empower clinics, health systems, and independent providers to enhance patient care and streamline clinical workflows. OCB and Mira Precision will collaborate to advance ToxNav® in the United States, establishing a substantial future market and sales presence.
Dr. David Kerr, Founder and Director of the Board of OCB, and Professor of Cancer Medicine at Oxford University, commented, 'We developed our ToxNav test to identify cancer patients that have a high likelihood of undergoing extreme toxicity to 5FU/capecitabine treatment, which is one of the most widely used cancer drugs in the world. We have already clinically proven that ToxNav identifies patients that are susceptible to extreme toxicity and are excited to have partnered the test with Mira Precision, who have complementary expertise to advance ToxNav in the USA. We look forward to a long and productive relationship with Mira Precision as we advance ToxNav to widen its clinical utility in the USA and save more patient lives.'
Dr. Sandra Gunselman, Founder and CEO of Mira Precision Health, said, 'I founded Mira Precision Health with the vision of bringing the most innovative and personalized diagnostic solutions to healthcare providers and their patients. Our collaboration with Dr. Kerr and the renowned team at Oxford Cancer Biomarkers marks an exciting inflection point for Mira, allowing us to partner with globally-respected academic medical centers and deliver advanced precision medicine directly into clinical practice. Together, we're committed to significantly improving patient care and outcomes across the United States.'
Karen Merritt, Co-Founder of Advocates for Universal DPD/DPYD Testing, comments, 'I strongly support the partnership between Oxford Cancer Biomarkers and Mira Precision Health, as it represents a critical step toward safer, more comprehensive pretreatment DPYD screening to prevent avoidable toxicity and save lives.'
ToxNav® enhances clinical decision-making through comprehensive genetic profiling, aligning directly with recent NCCN Guidelines updates that recommend DPYD testing for colorectal cancer patients receiving fluoropyrimidine-based treatments. Shaun Peterson, VP of Sales and Marketing at Mira Precision Health, noted, 'The NCCN revision underscores the timely clinical importance of the Mira Precision ToxNav® Test in the US market. Backed by multiple peer-reviewed studies and CE-IVD certification in the UK, ToxNav® significantly improves patient outcomes, reduces healthcare costs, and advances equitable precision medicine. This partnership between Oxford Cancer Biomarkers and Mira Precision Health reinforces our commitment to personalized cancer care innovation.'
Michele Blair, Director of Economic Development for the City of Mason, said, 'We are excited to partner with Mira Precision Health to further science partnerships like ToxNav. Using the Mason Living Lab we have been able to connect an educated population with new and growing health technology to achieve faster commercialization. The new Mira Precision ToxNav® Test is an excellent addition to our portfolio of technology.'
About Oxford Cancer Biomarkers Ltd (OCB)
Oxford Cancer Biomarkers (OCB) is a spin-out from the University of Oxford, developing and commercialising a suite of molecular and AI-enabled diagnostic tools that harness the analytical capabilities of pharmacogenomic markers and digital pathology to optimise cancer treatment pathways. OCB continues to expand its portfolio with novel biomarkers and proprietary algorithms that enable clinicians to make personalized treatment recommendations based on real-world evidence, empowering patients to make better-informed decisions about their own cancer therapy. Its most recent investment came from Plutus Investments Group LLP, which is a multi-family office backing entrepreneurs in Europe and the USA, focused on Life Sciences, Biotech, Fintech, and Tech investments.
For more information, please visit www.oxfordbio.com.
About Mira Precision Health, Inc.
Mira Precision Health was founded to provide advanced molecular diagnostic testing directly to healthcare providers and communities. Inspired by the empowerment and strength symbolized by the name 'Mira,' Founder and CEO Dr. Sandra J. Gunselman envisioned reshaping precision medicine by equipping clinics, health systems, and independent providers with cutting-edge clinical genomics, pharmacogenomics expertise, and data informatics tools. Mira Precision Health is dedicated to enhancing clinical decision support, improving patient safety, and delivering personalized, data-driven healthcare solutions that significantly elevate patient outcomes.
For more information, please visit www.miraprecision.com
About The City of Mason BioHub
Recognized as a leader in Ohio and the Midwest, the City of Mason BioHub is an established hub for biohealth and biotech life science companies, with focus areas in cardiology, mental health and precision medicine. With $600 million in new investment and more than 1,200 jobs announced in 2024 primarily in this sector, the City's Economic Development arm has created an unmatched model for scaling young growth companies. Through its proprietary Living Lab initiative, the City is able to leverage its diverse demographic population and scientific business community to scale young HealthTech companies, while improving personal health outcomes for residents. For more information about the City of Mason, visit www.whyMason.com or www.imagineMason.org.
For further information, please contact:
Oxford Cancer Biomarkers Ltd Tel: 0044 7976 708535
Mira Precision Health, Shaun Peterson, Vice President, Sales and Marketing, [email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/oxford-cancer-biomarkers-partners-with-mira-precision-health-to-advance-its-toxnav-test-for-predicting-patient-toxicity-to-5fucapecitabine-treatment-in-the-usa-302469984.html
SOURCE City of Mason
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
DRC Medicine Ltd. Announces the Business Combination Agreement with Ribbon Acquisition Corp.
Combined Company Expected to be Listed on NASDAQ Global Market DRC Medicine Ltd. ('DRC Medicine' or the 'Company'), is an innovative healthcare and biotechnology company headquartered in Japan, focused on the research, development, and commercialization of advanced medical technologies that address significant global health challenges. The Company is best known for its proprietary Hydro Silver Titanium® technology, initially applied in consumer hygiene products such as masks and towels, and now being advanced to obtain medical device certification as among the world's first therapeutic masks for seasonal allergic rhinitis. Combined company to have an implied initial pro forma equity value of approximately $422.15 Million, (assuming no redemptions) and the transaction is expected to deliver cash proceeds of around $50.42 Million to DRC Medicine (assuming no redemptions) to fund DRC Medicine's business and operations, which include devices' clinical trial and certification. Current DRC Medicine shareholders will retain 100% of their equity and will continue to own approximately 82.91% of the combined company on a pro forma basis, assuming no redemptions by Ribbon's shareholder. Tokyo, June 30, 2025 (GLOBE NEWSWIRE) — DRC Medicine Ltd., an innovative healthcare and biotechnology company based in Tokyo, Japan ('DRC' or the 'Company'), announced today that it has entered into a business combination agreement (the 'Business Combination Agreement') with Ribbon Acquisition Corp. (NASDAQ: RIBB) ('Ribbon'), a special purpose acquisition company, DRC Medicine Inc., a Delaware company limited by shares (DRC Medicine) and DRC Merger Inc. ('Merger Sub'), a Delaware company limited by shares and a directly owned subsidiary of DRC Medicine, which would result in DRC Medicine becoming a publicly-traded company (the 'Proposed Transaction'). DRC Medicine Ltd. is an innovative healthcare and biotechnology company headquartered in Japan, focused on the research, development, and commercialization of advanced medical technologies that address significant global health challenges. The Company is best known for its proprietary Hydro Silver Titanium® technology, initially applied in consumer hygiene products such as masks and towels, and now being advanced to obtain medical device certification as among the world's first therapeutic masks for seasonal allergic rhinitis. In addition to medical devices, the Company is developing a pipeline of In Vitro Diagnostic ('IVD') kits for infectious diseases and allergen detection, combining its world-only cell-free protein synthesis technology leveraging AI powered Apps and is in final negotiation in acquiring an innovative ATP-enhancing drug for Parkinson's disease drugs development company, the drug is currently in clinical trials. This diverse portfolio is driven by a strong focus on unmet medical needs, AI-assisted discovery, and global healthcare infrastructure transformation. For more information, visit and Dr. Marumi Okazaki, President & CEO of DRC, said: 'This transaction will give us the resources that will enable us to capture the positive trends in our industry. Given the growth of airborne allergens, respiratory diseases and infectious diseases, increasing demand for better respiratory protection mask and faster and a more accurate IVD kits, we intend to invest in more IVD kits paired with AI-powered Apps in achieving universal diagnostics to empower the general public in guarding their health and fight against allergen, respiratory diseases and infectious diseases as well as catapult our research and development, production capabilities to meet the rising demand for better respiratory protection mask and AI-powered IVD kits.' Mr. Angshuman (Bubai) Ghosh, Chairman/CEO of Ribbon, said, ' This business combination agreement with DRC is a great opportunity to enter into an exciting and accelerating growth healthcare and biotechnology industry. We believe its highly capable and experienced management team with all of the founders with substantial experience in developing innovative technologies, supported by their technology-savvy specialists and R&D team who are committed to pioneering innovations, will enable DRC to continuously innovate and advance their healthcare and biotechnology applications to gain a greater foothold in the global market.' Transaction Overview As a part of the Proposed Transaction, an intermediate holding company incorporated in Japan (the 'Intermediate Co.' will acquire the shares of DRC Medicine, after which the Intermediate Co. will engage in a share exchange transaction with the shareholders of the Company, such that the Company will become a wholly-owned subsidiary of Intermediate Co. and the shareholders of the Company will become shareholders of DRC Medicine (the 'DRC Restructuring'). Following the consummation of the DRC Restructuring and subject to the terms and conditions of the Business Combination Agreement, Ribbon will merge with and into the Merger Sub, with Merger Sub continuing as the surviving company and remaining a wholly owned subsidiary of DRC Medicine. The Proposed Transaction implies a pre-money equity value of US$350 million of DRC on a fully diluted basis, and is expected to provide DRC with access to approximately US$50 million cash from Ribbon's IPO proceeds held in trust, assuming no redemption by Ribbon's shareholders in connection with the current and future proxy exercises and prior to the payment of any transaction expenses. The parties will cooperate in connection with any financing arrangement the parties seek in connection with the Proposed Transaction. Advisors A.G.P./Alliance Global Partners serves as the financial advisor and lead capital markets advisor to Ribbon. Geneva Capital Group serves as the financial advisor to DRC. Celine & Partners serves as the legal advisor to Ribbon. Ross Law Group serves as the legal advisor to DRC. About DRC Medicine Ltd . Founded in 2007, DRC is an innovative healthcare and biotechnology company headquartered in Japan, focused on the research, development, and commercialization of advanced medical technologies that address significant global health challenges. The Company is best known for its proprietary Hydro Silver Titanium® technology, initially applied in consumer hygiene products such as masks and towels, and now being advanced to obtain medical device certification as among the world's first therapeutic masks for seasonal allergic rhinitis . In addition to medical devices, the Company is developing a pipeline of In Vitro Diagnostic ('IVD') kits for infectious diseases and allergen detection, combining its world-only cell-free protein synthesis technology leveraging AI powered Apps and is in final negotiation in acquiring an innovative ATP-enhancing drug for Parkinson's disease. About Ribbon Acquisition Corp . Ribbon is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. While Ribbon intends to conduct a global search for target businesses without being limited by geographic region, certain executive officers and independent directors are based in Hong Kong, and certain executive officers have experience investing in and building businesses in the Asia Pacific region and have a deep understanding of the region's business environment, regulations, regulatory bodies and culture. Ribbon will not undertake an initial business combination with any company being based in or having the majority of the company's operations in Greater China. Ribbon is led by Mr. Angshuman (Bubai) Ghosh, Ribbon's Chief Executive Officer, and Ms. Zhiyang (Anna) Zhou, Ribbon's Chief Financial Officer. Important Additional Information Regarding the Transaction Will Be Filed With the SEC This press release relates to the proposed business combination between Ribbon Acquisition Corp. and DRC Medicine Ltd.. This press release does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. DRC intends to file a Registration Statement on Form S-4 with the SEC, which will include a document that serves as a joint prospectus and proxy statement, referred to as a proxy statement/prospectus. A proxy statement/prospectus will be sent to all Ribbon shareholders. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom. Ribbon and DRC will also file other documents regarding the proposed business combination with the SEC. This press release does not contain all the information that should be considered concerning the proposed business combination and is not intended to form the basis of any investment decision or any other decision in respect of the business combination. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS OF RIBBON ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED BUSINESS COMBINATION AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED BUSINESS COMBINATION. Investors and security holders will be able to obtain free copies of the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Ribbon and DRC through the website maintained by the SEC at The documents filed by Ribbon and DRC with the SEC also may be obtained free of charge upon written request to Ribbon Acquisition Corp., Central Park Tower LaTour Shinjuku Room 3001, 6-15-1 Nishi Shinjuku, Shinjuku-ku Tokyo 160-0023. Participants in the Solicitations Ribbon, DRC and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies from Ribbon's shareholders in connection with the proposed business combination. You can find information about Ribbon's directors and executive officers and their interest in Ribbon in Ribbon's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was originally filed with the SEC on April 1, 2025. A list of the names of the directors, executive officers, other members of management and employees of Ribbon and DRC, as well as information regarding their interests in the business combination, will be contained in the Registration Statement on Form S-4 to be filed with the SEC by DRC. Additional information regarding the interests of such potential participants in the solicitation process may also be included in other relevant documents when they are filed with the SEC. You may obtain free copies of these documents from the sources indicated above. Caution About Forward-Looking Statements This press release may contain forward-looking statements within the meaning of section 27A of the U.S. Securities Act of 1933, as amended (the 'Securities Act'), and section 21E of the U.S. Securities Exchange Act of 1934 ('Exchange Act') that are based on beliefs and assumptions and on information currently available to Ribbon and DRC. These forward-looking statements are based on Ribbon's and DRC's expectations and beliefs concerning future events and involve risks and uncertainties that may cause actual results to differ materially from current expectations. In some cases, you can identify forward-looking statements by the following words: 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing,' 'target,' 'seek' or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including projections of market opportunity and market share, the capability of DRC's business plans including its plans to expand, the anticipated enterprise value of the combined company following the consummation of the proposed business combination, anticipated benefits of the proposed business combination and expectations related to the terms and timing of the proposed business combination, are also forward-looking statements. Although each of Ribbon and DRC believes that it has a reasonable basis for each forward-looking statement contained in this communication, each of Ribbon and DRC cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. These factors are difficult to predict accurately and may be beyond Ribbon's and DRC's control. In addition, there will be risks and uncertainties described in the proxy statement/prospectus on Form S-4 relating to the proposed business combination, which is expected to be filed by DRC with the SEC and other documents filed by Ribbon or DRC from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those expressed or implied in the forward-looking statements. There may be additional risks that neither Ribbon or DRC presently know or that Ribbon and DRC currently believe are immaterial and that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by Ribbon or DRC, their respective directors, officers or employees or any other person that Ribbon and DRC will achieve their objectives and plans in any specified time frame, or at all. Forward-looking statements in this communication or elsewhere speak only as of the date made. New uncertainties and risks arise from time to time, and it is impossible for Ribbon or DRC to predict these events or how they may affect Ribbon or DRC. Except as required by law, neither Ribbon nor DRC has any duty to, and does not intend to, update or revise the forward-looking statements in this communication or elsewhere after the date this communication is issued. In light of these risks and uncertainties, investors should keep in mind that results, events or developments discussed in any forward-looking statement made in this communication may not occur. Uncertainties and risk factors that could affect Ribbon's and DRC's future performance and cause results to differ from the forward-looking statements in this release include, but are not limited to: the occurrence of any event, change or other circumstances that could give rise to the termination of the business combination; the outcome of any legal proceedings that may be instituted against Ribbon or DRC, the combined company or others following the announcement of the business combination; the inability to complete the business combination due to the failure to obtain approval of the shareholders of Ribbon or to satisfy other conditions to closing; changes to the proposed structure of the business combination that may be required or appropriate as a result of applicable laws or regulations; the ability to meet stock exchange listing standards following the consummation of the business combination; the risk that the business combination disrupts current plans and operations of Ribbon or DRC as a result of the announcement and consummation of the business combination; the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and retain its management and key employees; costs related to the business combination; changes in applicable laws or regulations; Ribbon's estimates of expenditures and profitability and underlying assumptions with respect to shareholder redemptions and purchase price and other adjustments; the impact of the COVID-19 pandemic; changes in laws and regulations that impact DRC; ability to enforce, protect and maintain intellectual property rights; and other risks and uncertainties set forth in the section entitled 'Risk Factors' and 'Cautionary Note Regarding Forward-Looking Statements' in Ribbon's final prospectus dated January 14, 2025 relating to its initial public offering and in subsequent filings with the SEC, including the registration statement on Form S-4 relating to the business combination expected to be filed by DRC. No Offer or Solicitation This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom. For further queries please contact: Geneva Capital Group on behalf of DRC Bob Lau, [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Wire
3 hours ago
- Business Wire
Transition Industries簽署全球最大的獨立超低碳化學品生產設施Pacifico Mexinol專案策略協議
墨西哥市--(BUSINESS WIRE)--(美國商業資訊)-- 北美地區世界一流規模的淨零碳排放甲醇及綠色氫氣專案開發商 Transition Industries LLC 與由 Samsung E&A Co., Ltd. (Samsung E&A)、Grupo Samsung E&A Mexico, S.A. de C.V.以及 Techint Engineering and Construction 組成的聯盟就位於位於墨西哥錫那羅亞州阿奧梅市的 Pacifico Mexinol 專案簽署了工程總承包(EPC)合約。本次簽約儀式在滿足特別先決條件及獲得全部必要核准後正式生效。 MAIRE 集團旗下科技公司NextChem透過其子公司KT TECH SpA，就為該專案供應NX AdWinMethanol®Zero專有技術的事宜，與Samsung E&A簽署了基礎工程設計、關鍵和專利設備供應協議。 Transition Industries正在與World Bank Group成員 International Finance Corporation (IFC)合作開發Pacifico Mexinol專案。該專案計畫於2029年投產，屆時將成為全球最大的獨立超低碳化學品生產設施——每年透過碳捕捉技術和天然氣生產約35萬公噸綠色甲醇及180萬公噸藍色甲醇。 Transition Industries執行長Rommel Gallo表示：「今天的簽約儀式是Pacifico Mexinol專案的重大里程碑，讓我們得以展示與韓國Samsung E&A、墨西哥Techint及義大利MAIRE Group的世界一流創新與合作。這也為2025年專案動工奠定基礎，兌現我們在墨西哥打造全球最具永續性大型專案的堅定承諾。」 出席活動的包括聯邦、州和市政官員，以及參與這一全球性專案的各國大使。 IFC代表亦到場見證，其他策略商業合作夥伴也將為專案提供綠色氫能、全球最大工業廢水循環利用系統等尖端科技與工程方案。 Transition Industries預期今年夏天將簽署更多策略協議並實現重要里程碑。該專案擬做為規模化超低碳化學品典範案例，亮相2025年11月在巴西貝倫舉行的第30屆聯合國氣候變遷大會(COP30)。 免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。
Yahoo
5 hours ago
- Yahoo
Western Uranium & Vanadium Announces Results of AGM and Appoints New Transfer Agent
Toronto, Ontario and Nucla, Colorado, June 30, 2025 (GLOBE NEWSWIRE) -- Western Uranium & Vanadium Corp. (CSE: WUC) (OTCQX: WSTRF) ('Western' or the 'Company') is pleased to announce the results of the Company's Annual General and Special Meeting of shareholders (the 'Meeting') held in Nucla, Colorado on June 27, 2025. Proxy votes were cast for common shares representing approximately 51% of the issued and outstanding common shares of the Company as at the record date for the Meeting. Each of the other matters put forward before shareholders for consideration and approval at the Meeting, as described in the Company's management information circular dated May 22, 2025, was duly approved by the requisite number of votes. Re-Election of DirectorsAt the Meeting, the shareholders re-elected all of the directors proposed by management of the Company, namely, George Glasier, Bryan Murphy, Andrew Wilder and Michael Skutezky. Re-Appointment of AuditorThe shareholders re-appointed MNP LLP as auditor of the Company for the ensuing year and authorized the board of the Company to fix the remuneration of the auditors. Re-Appointment of OfficersSubsequent to the Meeting, the following management re-appointments were confirmed for the ensuing year: George Glasier, President and Chief Executive Officer; Robert Klein, Chief Financial Officer; Michael Rutter, Chief Operating Officer; and Denis Frawley, Corporate Secretary. The newly-elected Board re-appointed the following chairs: Bryan Murphy as Chairman of the Board; Andrew Wilder as Chairman of the Audit Committee; and Michael Skutezky as Chairman of the Governance, Nominating and Compensation Committee. Each of the Audit Committee Governance, and the Governance, Nominating and Compensation Committee are comprised of three independent directors, namely Bryan Murphy, Andrew Wilder, and Michael Skutezky. Appointment of New Transfer AgentWestern's announces that it has appointed Odyssey Trust Company ("Odyssey") as the registrar and transfer agent for the Company's common shares replacing Capital Transfer Agency ULC ('CTA'). There was no change to the CUSIP number of Western's common sharesas a result of the change of registrar and transfer agent. Going forward, inquiries and correspondence relating to shareholders' records should be directed to Odyssey at In addition, Odyssey has replaced CTA as rights agent under the shareholder rights plan agreement of the Company dated May 24, 2023. Shareholders need not take action in respect of the change in transfer agent and rights Western Uranium & Vanadium Uranium & Vanadium Corp. is ramping-up high-grade uranium and vanadium production at its Sunday Mine Complex. In addition to the flagship property located in the prolific Uravan Mineral Belt, the production pipeline also includes conventional projects in Colorado and Utah. The Mustang Mineral Processing Site is being licensed and developed for mined material recovery and will incorporate kinetic separation to optimize economics. Cautionary Note Regarding Forward-Looking Information: Certain information contained in this news release constitutes 'forward-looking information' or 'forward-looking statements' within the meaning of applicable securities laws (collectively, 'forward-looking statements'). Statements of that nature include statements relating to, or that are dependent upon: the Company's expectations, estimates and projections regarding the Offering and exploration and production plans and results; the timing of planned activities; whether the Company can raise any additional funds required to implement its plans; whether regulatory or analogous requirements can be satisfied to permit planned activities; and more generally to the Company's business, and the economic and political environment applicable to its operations, assets and plans. All such forward-looking statements are subject to important risk factors and uncertainties, many of which are beyond the Company's ability to control or predict. Please refer to the Company's most recent Management's Discussion and Analysis, as well as its other filings at and/or for a more detailed review of those risk factors. Readers are cautioned not to place undue reliance on the Company's forward-looking statements, and that these statements are made as of the date hereof. While the Company may do so, it does not undertake any obligation to update these forward-looking statements at any particular time, except as and to the extent required under applicable laws and regulations. FOR ADDITIONAL INFORMATION, PLEASE CONTACT: George GlasierPresident and CEO 970-864-2125gglasier@ Robert KleinChief Financial Officer908-872-7686rklein@
